Our data suggest that IAP inhibitors may impact both immune infiltration and tumor-killing phase in part through restoring tumoral STING expression, reinvigorating STING-mediated DNA-sensing pathway, re-inducing innate immunity cytokine and chemokine production, promoting chemotaxis of immune cells, and re-sensitizing tumors to IFNγ-mediated immune responsiveness. The gene discussed is STING1; the disease is neoplasm.